(Q34554722)

3 August 2017

1 reference

title

Treatment of Epstein-Barr virus-associated malignancies with specific T cells (English)

1 reference

3 August 2017

0 references

2

Helen E Heslop

1 reference

3 August 2017

Stephen Gottschalk

1

1 reference

3 August 2017

Cliona M Roon

series ordinal

3

1 reference

3 August 2017

publication date

1 January 2002

1 reference

Advances in Cancer Research

3 August 2017

published in

1 reference

3 August 2017

volume

84

1 reference

3 August 2017

page(s)

175-201

1 reference

Phenotypic analysis of antigen-specific T lymphocytes

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Primary central nervous system malignant non-Hodgkin's lymphomas from HIV-infected and non-infected patients: expression of cellular surface proteins and Epstein-Barr viral markers.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

The ins and outs of EBV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: case-control and historical cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

CD40 cross-linking enhances the immunogenicity of Burkitt's-lymphoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Adoptive cellular immunotherapy for EBV lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Donor T cells to treat EBV-associated lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

HLA-A alleles of patients with pyothorax-associated lymphoma: anti-Epstein-Barr virus (EBV) host immune responses during the development of EBV latent antigen-positive lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

A perspective on monoclonal antibody therapy: where we have been and where we are going

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Monoclonal antibodies in lymphoid neoplasia: principles for optimal combined therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

An animal model for acute and persistent Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Donor lymphocyte transfusion for the treatment of Epstein-Barr virus-associated lymphoproliferative disorder of the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Feasibility of cellular adoptive immunotherapy for Epstein-Barr virus-associated lymphomas using haploidentical donors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Immune escape mechanisms in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

T-cell therapy of cytomegalovirus and human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Pediatric solid-organ transplant recipients carry chronic loads of Epstein-Barr virus exclusively in the immunoglobulin D-negative B-cell compartment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Epstein-Barr virus-associated lymphoproliferative disorder after unrelated bone marrow transplantation in a young child with Wiskott-Aldrich syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Presentation of epstein-barr virus latency antigens to CD8(+), interferon-gamma-secreting, T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

The Epstein-Barr virus:host balance in acute infectious mononucleosis patients receiving acyclovir anti-viral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

The expression and function of Epstein-Barr virus encoded latent genes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2984006-4

7 January 2021

10.1016/S0065-230X(02)84006-4

Identifiers

DOI

1 reference

3 August 2017

1 reference